Davunetide vs TRH

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Hypothalamic tripeptide (pGlu-His-Pro-NH2); binds TRH-R1/R2; stimulates TSH/prolactin release; direct CNS effects independent of thyroid axis including synaptic potentiation

Thyrotropin-releasing hormone (TRH) is a hypothalamic tripeptide that serves as the primary regulator of TSH secretion from the pituitary gland but is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic neurotransmitter systems independent of its thyroid axis role. Beyond endocrine function, centrally administered TRH exerts arousal-promoting effects and has been shown in preclinical models to prevent depletion of cortical acetylcholine and monoamines following brain injury, suggesting a neuroprotective neuromodulatory role. Controlled human research has demonstrated that TRH attenuates scopolamine-induced memory impairment, consistent with its proposed role in potentiating cholinergic signaling and providing direct evidence for central cognitive effects of the parent compound. TRH is used clinically as a diagnostic agent (protirelin) for thyroid function testing; as a cognitive or neuroprotective agent it remains investigational, with no approved indication for these uses and human evidence limited to small mechanistic studies. TRH in neuroendocrinology and nootropic research Beyond its role as a hypophysiotropic releasing factor, TRH functions as a neuromodulator throughout the CNS. TRH receptors (TRH-R1 and TRH-R2) are expressed in the cerebral cortex, hippocampus, limbic system, and spinal cord, mediating effects on arousal, mood, and locomotor activity independent of the pituitary-thyroid axis. Animal studies document TRH's analeptic properties — the peptide can rapidly reverse sedation from barbiturates, ethanol, and opioids, suggesting a direct CNS excitatory role. This arousal-promoting effect has attracted research interest in fatigue, cognitive impairment, and as an emergency reversal agent in overdose contexts, though clinical translation has been limited by TRH's very short half-life (approximately 5 minutes in plasma due to rapid enzymatic degradation). Taltirelin (TA-0910), a more metabolically stable TRH analogue, is approved in Japan for spinocerebellar degeneration — the only approved clinical application in this research space. The TRH stimulation test (200–500mcg IV bolus with serial TSH/prolactin sampling) has been used diagnostically, though modern ultrasensitive TSH assays have largely replaced it. Exogenous TRH for nootropic or energy applications is available as a research peptide; intranasal delivery to bypass peripheral degradation has been explored in preclinical work.